News and Trends 7 Sep 2017 Circassia Moves Away from a Failed Allergy Pipeline with Phase III Success Circassia has positive Phase III results from its respiratory pipeline, great news for the company after abandoning its allergy immunotherapies due to clinical failure. Circassia Pharmaceuticals, based in Oxford, has reported a Phase III success with Duaklir, a drug combination for the treatment of chronic obstructive pulmonary disease (COPD). The trial was run by AstraZeneca, […] September 7, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 7 Sep 2017 CAR-T is Nearly Here: How Will It Be Delivered? As we anticipate the first-ever CAR-T therapy market approval we look at the important aspect of treatment delivery and viral vector strategies. Cell and gene therapy is increasingly coming into its own with some of the major pharma players releasing big headlines. GlaxoSmithKline (GSK) released the first ex vivo stem cell therapy in May 2016 […] September 7, 2017 - 4 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 6 Sep 2017 Tiziana‘s Antibody Formulation Enters Phase IIa Trial for Liver Disease Treatment Tiziana makes moves towards a €37B market with an oral monoclonal antibody (mAb) formulation to treat non-alcoholic steatohepatitis (NASH) . Tiziana, which has previously developed compounds targeting the second most deadly form of cancer, has produced a novel formulation of the anti-CD3 mAb, Foralumab. The biologic will be tested in patients with NASH and other […] September 6, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 6 Sep 2017 MSD Offers €464M to Buy German Biotech Fighting Cancer with RNA MSD is back in the RNA field with the acquisition of Rigontec, a German biotech harnessing RNA interference to make the immune system attack cancer cells. After selling selling Sirna Therapeutics three years ago for almost a tenth of the acquisition price, it seemed like MSD was out of the RNA field. However, the big […] September 6, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 6 Sep 2017 A €344M Partnership will Develop Bicycle Drugs for Hemophilia Bicycle Therapeutics has partnered with Bioverativ to develop a new class of drugs for patients with rare blood disorders like hemophilia and sickle cell disease. Bicycle Therapeutics, a money-magnet biotech founded by Greg Winter, has closed a deal with US firm Bioverativ for the discovery, development and commercialization of bicycle drugs for rare blood disorders. […] September 6, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 6 Sep 2017 Europe Gives the Antibiotic Resistance Fight a Major Cash Injection Six European countries, the UK’s Wellcome Trust and South Africa have committed €56.5M to the GARDP to work on breaking antibiotic resistance. The Global Antibiotic Research and Development Partnership (GARDP) has received this week €56.5M of funding to boost its activity, focused in promoting the development of new antibiotics. The investment comes mainly from Germany, […] September 6, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 6 Sep 2017 What to Do When the Microorganisms Get to You For the first time ever an injectable clinical batch has been manufactured with the help of single-use technologies. A great way of fighting unwanted contamination in drug development! Have you ever opened a petri-dish and found an unknown growth on your medium? The same medium you had carefully prepared by meticulously spreading the sample over […] September 6, 2017 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Interview 6 Sep 2017 The CAR-T Race is Far from Over: This CEO is Exploring a New Avenue Gilead has just splashed out $12 billion for Kite Pharma, and the FDA is currently reviewing Novartis’ Marketing Approval Application for the first-ever CAR-T therapy. I sat down with Gregg Sando of Cell Medica to hear the perspective of a biotech vying for a piece of the pie. Though he spent 20 years in investment […] September 6, 2017 - 6 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 5 Sep 2017 FREE TICKET Giveaway – European Antibody Congress Our wonderful readers now have the chance to win a FREE ticket for the European Antibody Congress in Basel, Switzerland! On 31st October – 2nd November you will have the opportunity to participate in a vibrant gathering with more than 200 speakers and 650 influential decision makers from across academia and the biotech and pharmaceutical industry! Apply today and […] September 5, 2017 - 2 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 5 Sep 2017 French Biotech Lures Big Pharma with Fibrosis Treatments This week, Inventiva has received a milestone payment from Boehringer Ingelheim and extended its collaboration with AbbVie. Today, Boehringer Ingelheim has decided today to take the next step forward and start development of the first candidate against idiopathic pulmonary fibrosis (IPF) from a research partnership with Inventiva. This has triggered a €2.5M payment for the French biotech, which is […] September 5, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 5 Sep 2017 Swiss Biotech Raises €8M in First Closing of Series B to Develop Cancer Vaccines AMAL Therapeutics has raised €8M to push its colorectal cancer vaccine ATP128 into clinical trials and keep developing its tumor vaccine pipeline. AMAL Therapeutics, a young biotech based in Geneva, is getting a boost for its pipeline of cancer vaccines thanks to a new funding round. The first tranche of its Series B fundraising has gathered €8M (CHF 8.8M) […] September 5, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 5 Sep 2017 UPDATE: Austrian Biotech receives €3.3M boost for its Chikungunya Vaccine UPDATE (05/09/2017): Innovate UK has granted Themis £3M (€3.3M) to push its Chikungunya Vaccine towards Phase III. Originally Published 06/06/2017 Themis Bioscience will test its vaccine candidate against Chikungunya fever in a new Phase I/II trial sponsored by the NIH. Based in Vienna, Themis Bioscience develops new vaccine candidates for emerging diseases like Zika and Chikungunya with its virus […] September 5, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email